Advantages of efficacy and safety of fixed-dose tafluprost/timolol combination over fixed-dose latanoprost/timolol combination

Fuwa M., Ueda K., Akaishi T., Yamashita N., Kirihara T., Shimazaki A., Mano H., Kawazu K.

2016
PLoS ONE

View publication

Therapeutic Area

Glaucoma
Categories

Preclinical development

Affiliations

Global Research and Development, Santen Pharmaceutical Co., Ltd., Ikoma-shi, Nara, Japan

Related Publications

Posterior Ciliary Artery Contraction by Bradykinin Receptor Subtypes and Implications for Retinal Blood Flow Dysfunction

Sharif NA, Ohia SE, Kulkarni-Chitnis M, Okolie A, Chaudhry SD, Njie-Mbye YF

Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A 3-Year Prospective Study

Akagi T, Fukuchi T, Higashide T, Udagawa S, Ohkubo S, Sugiyama K, Tanihara H, Araie M, Tomita G, Matsumoto C, Tomidokoro A, Hangai M, Kawata H, Inai M, Tanaka Y; SVF Prospector Study Group.

Cost-utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain

Canut MI, García-Feijoo J, Larrosa-Poves JM, López-López F, Pazos M, Espinoza-Cámac N, Oyagüez I, Del Rio T, Rodríguez M.

View all Glaucoma publications